Bepirovirsen (Hibsago)

All References

• Bouquet J, Speer SD, Koenig A, et al. Single nucleotide polymorphisms in the bepirovirsen binding site have limited impact on treatment response in chronic hepatitis B. J Hepatol. 2026;84:887-97.
  [PubMed Abstract]
• Buti M, Heo J, Tanaka Y, et al. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B. J Hepatol. 2025;82:222-34.
  [PubMed Abstract]
• Delahaye JL, You S, Fu K, et al. Bepirovirsen induces innate immune proteins independent of HBV. Hepatol Int. 2026;20:1318-28.
  [PubMed Abstract]
• Ermler ME, Delahaye JL, Jordan W, et al. Bepirovirsen induces innate immune activation in the liver potentially through TLR8 signaling. JHEP Rep. 2026;8:101923.
  [PubMed Abstract]
• Han K, Youssef AS, Magee M, et al. Lack of Pharmacokinetic Drug-Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs. Clin Pharmacol Drug Dev. 2025;14:281-91.
  [PubMed Abstract]
• Hou J, Lim SG, Buti M, et al. Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. N Engl J Med. 2026;394:2395-2406.
  [PubMed Abstract]
• Sun Y, Gao J. Bepirovirsen: The first antisense oligonucleotide approved to achieve a functional cure for chronic hepatitis B. Drug Discov Ther. 2026 Sep 25. Online ahead of print.
  [PubMed Abstract]
• Youssef AS, Shah P, Hu M, et al. A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants. Clin Pharmacol Drug Dev. 2026;15:e1615.
  [PubMed Abstract]
• Yuen MF, Heo J, Jang JW, et al. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med. 2021;27:1725-34.
  [PubMed Abstract]
• Yuen MF, Lim SG, Plesniak R, et al. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. N Engl J Med. 2022;387:1957-68.
  [PubMed Abstract]
• Zeng QL, Fu J. Bepirovirsen improves the functional cure of chronic hepatitis B through novel mechanisms. Infect Dis Immun. 2026;6:245-7.
  [PubMed Abstract]